Safety and Efficacy Study of Flebogamma 5% DIF IGIV in Pediatric Subjects
Phase 4
Completed
- Conditions
- Primary Immune Deficiency Disease
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Instituto Grifols, S.A.
- Target Recruit Count
- 24
- Registration Number
- NCT00634569
- Locations
- 🇺🇸
University of South Florida, St. Petersburg, Florida, United States
🇺🇸Family Allergy & Asthma Center, PC, Atlanta, Georgia, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States